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Abstract
Glioblastoma (GB) remains one of the most difficult challenges for neurosurgeons
due to its highly vascularized and complex characteristics. Focused ultrasound (FUS)
is quickly being integrated into GB research thanks to its ability to treat tumors a
distance away from the transducer without harming healthy tissues in its path.
Presented here is a comprehensive review of FUS therapies for GB treatment.
Therapies include thermal ablation, blood-brain barrier opening, radiosensitization,
sonodynamic therapy, and immunomodulation, all of which have the potential to
change GB treatment regimens.
This thesis reports a minimally invasive high-intensity focused ultrasound (HIFU)
probe designed for brain surgery. It has been reduced in size from its previous
generation and now possesses steering capabilities in the axial direction. This could
take the place of some recurrent GB resection surgeries.
Also presented here is a phantom study for a commercial magnetic resonance
guided focused ultrasound system, the RK-300, which has the ability to perform most
of the therapies mentioned above. The phantom study confirms the functionality of
the system, which after lying dormant for a few years is now ready for laboratory
research.
In transitioning FUS to the clinical setting, there needs to be real-time methods of
monitoring surrounding tissue. Here, a fiber optic temperature sensor the width of
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"It is not the critic who counts; not the man who points out how
the strong man stumbles, or where the doer of deeds could have
done them better. The credit belongs to the man who is actually
in the arena, whose face is marred by dust and sweat and blood;
who strives valiantly; who errs, who comes short again and again,
because there is no effort without error and shortcoming; but
who does actually strive to do the deeds; who knows great
enthusiasms, the great devotions; who spends himself in a
worthy cause; who at the best knows in the end the triumph of
high achievement, and who at the worst, if he fails, at least fails
while daring greatly, so that his place shall never be with those
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Neoplasms, commonly known as tumors, are an abnormal growth of tissue that
arises from continuous cell division or prolonged cell survival. Benign neoplasms may
grow to a considerable size, which may lead to other serious issues, but do not invade
surrounding tissues or typically metastasize. Malignant neoplasms, in addition to
growing, invade surrounding tissues and frequently have a propensity to metastasize
to other organs [1]. Neuro-oncology is the study and treatment of neoplasms that
involve the brain or spinal cord, including, but are not limited to meningiomas,
oligodendrogliomas, astrocytomas, medulloblastomas, and glioblastomas [2]. GBs are
the most common malignant primary brain tumors, accounting for 50% of primary
malignant brain tumors and 15% of all central nervous system tumors [3]. GBs are
aggressive, invasive, and result in the shortest patient survival rate for malignant brain
tumors (as seen in Table 1-I).
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Table 1-I. Brain Tumor Average 5 Year Survival
Tumor Type Average 5 Year Survival Rate (%) [4]







Clinical Treatment Regimen Today
Conventional therapies are aimed at removing, reducing, or slowing the growth of
the tumor mass. Radiation therapy uses high doses of radiation to kill cancer cells
and to slow the growth of cancer by destroying its DNA. External radiotherapy is
the most common form of radiation treatment and the least invasive, as it aims an
external beam of radiation at a specific cancer region. The other form of radiation
therapy is internal radiation, which is more invasive and involves potential risks. In
this treatment, radiation is injected into the body via a solid or liquid and works to
destroy the cancer; but unfortunately, this may also harm healthy cells [5]. Oftentimes
radiation is used in combination with surgical resection and/or chemotherapy to treat
GBs. Radiation alone or with initial surgery typically only results in a survival of
12 months [6]. Radiation combined with chemotherapy usually only increases that
survival time to 15 months [6].
Chemotherapy is a cancer treatment that uses chemotherapeutic agents to kill
cells that grow and divide quickly, typically a selective characteristic of cancer cells.
These particular drugs can be administered in various ways: infusions, injections,
pills, creams, specific cavity injections, and dissolvable wafers [7]. Chemotherapy is
often successful in treating various types of cancer, but faces a major challenge when
it comes to brain cancer: the blood-brain barrier (BBB). The BBB is a protective
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element between circulating blood and neural tissue, keeping possible toxins and
pathogens separated from the brain. It consists of endothelial cells which form tight
junctions, only allowing small agents through to the brain [8]. Chemotherapy agents
are often too large to cross the BBB and thus, are not an appropriate noninvasive form
of treatment. Among the few agents that can cross the BBB, temozolomide (TMZ) is
a common choice for treatment. However, in patients with early GB diagnosis, TMZ
is only shown to increase survival time by 2.5 months [4]. To account for the BBB
challenge, oftentimes after surgical resection of the tumor, wafers are placed in the
surrounding area to gradually release chemotherapy agents in the cancer area over
time [9].
Surgical procedures that are performed include biopsies and resections. Biopsies,
typically needle biopsies for GBs, can determine pathological diagnosis of the tumor
mass and help guide treatment [10]. Resections are generally performed in an attempt
to remove the tumor mass. However, due to the infiltrative nature of GBs, even
apparent gross total resections are unable to excise all of the tumor cells, often
resulting in tumor recurrence [11]. Therefore, for the treatment of GBs, resections
are aimed to relieve the mass effect of the tumor [10, 11]. Craniotomies, both asleep
and awake, are the most common surgical procedures in the treatment of GBs [10].
Maximally resected tumors result in an improved prognosis. Greater than 70% of
tumor volumes excised are accompanied by a statistically significant survival rate
[12], with a larger than 90% extent of resection having a greater one-year survival
rate. Excised tumor volumes larger than 95% may be difficult to achieve and may risk
neurological deficits [11]. Maximal tumor resection is often followed by radiation and/or
chemotherapy [10]. Resections are considerably invasive and risky. Complications like
neurological deficits can affect quality of life and unclear resection margins can cause
the tumor to recur [12]. Resection as a treatment option is sometimes excluded if the
tumor is deep seated or surrounded by eloquent brain matter [11].
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The above-mentioned drawbacks arising from conventional therapies drives the
need for more minimally invasive methods with reduced physiological side-effects. FUS




Ultrasound refers to sound waves at frequencies greater than the human auditory
range (>20,000 Hz). Ultrasound transducers, comprised of piezoelectric crystals,
vibrate when exposed to voltage. The waves generated from the vibrations travel
throughout the medium in contact with the transducer and cause the medium to
vibrate at the same frequency. In sonography applications, transducers are flat or
convex and can receive the response waves generated from the vibrating medium to
reconstruct an image. In FUS, the transducers are concave, so the ultrasound waves
emitted converge at a focal point within the medium. The acoustic energy at this focal
point can be used for various therapies (see Fig. 1-1) specific to treatments for GB:
thermal ablation, chemotherapy-aided BBB opening, radiosensitization, sonodynamic
therapy (SDT), immunomodulation, etc.
4
Figure 1-1. Treatment for GB: Applications of Focused Ultrasound (reproduced with
permission from [13])
Thermal Ablation
Thermal ablation requires the use of HIFU to generate temperatures capable of
resulting in tissue death, also known as necrosis. Temperatures above 60°C can easily
cause instantaneous necrosis for most cell types [14]. The goal of this therapy is quite
similar to surgical resection: lysing the entire tumor mass along with a 5-10 mm
margin of surrounding normal tissue. The necrotic mass is then absorbed by the body
over several months [15].
In order to achieve such high temperatures via transcranial, or non-invasive
ultrasound, the frequency of the ultrasonic waves should be at least 650 kHz to reach
deep-seated tumors (GBs, etc.) [16]. The thickness of the human skull, which is
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about 6-9mm [17], causes significant attenuation of ultrasound. To account for such
attenuation during thermal ablation, high powers up to 950 Watts are necessary for
allowing acoustic waves to propagate through the skull. Unfortunately, this results in
the skull absorbing the attenuated waves and an increase in temperature to dangerous
levels, so several cooling down periods are required. An example of this is when
Coluccia et al., performed the first non-invasive transcranial thermal ablation of GB
[16]. The procedure lasted 5 hours with the patient awake lying in the supine position
inside the magnetic resonance imaging (MRI) scanner. Long cool down breaks were
required between short FUS exposures. Multiple points of ablation were visible in the
tumor, but the entire tumor could not be ablated within this one treatment. Despite
the advantages of a non-invasive procedure (i.e., closed skull, less risk of infection),
the patient suffers due to a long and uncomfortable process that leaves parts of the
tumor untreated.
Due to the disadvantages and complications of non-invasive thermal ablation,
researchers are investigating minimally invasive HIFU procedures, where a small
portion of the skull is removed, helping to eliminate the attenuation caused by the
skull [18–20].
Enhanced Chemotherapy via BBB Opening
The BBB, while protective in many respects, often presents a blockade during
chemotherapy drug delivery, especially in the case of GB. Although GBs commonly
disrupt portions of the BBB, they are also highly vascularized and diffuse into healthy
brain tissue that is still protected by the BBB. This results in significantly lower chemo-
agent concentrations in the peritumoral tissue compared to the tumor center [21].
Fortunately, the BBB can be opened through various mechanisms: FUS, photochemical
internalization, photodynamic therapy, etc. [22]. FUS has gained significant traction
for this application due to its non-invasive characteristics. FUS has the ability
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to locally and temporarily open the BBB when applied in combination with an
injection of microbubbles. Available in various sizes, microbubbles typically consist
of gas contained in a synthesized phospholipid shell [23]. After systemic injection,
microbubbles circulating past the BBB will expand and contract when exposed to FUS,
leading to cavitation effects. This cavitation applies pressure to the BBB, eventually
opening a small portion to allow for temporary passage of drug-based treatments
[22]. Depending on the ultrasound parameters, microbubbles may be destroyed by
ultrasound or they will be cleared via the reticuloendothial system [24]. Mainprize et
al. treated 5 patients with high-grade gliomas using chemotherapy in combination
with FUS BBB opening. After receiving treatment, surgical resection was performed,
in which sonicated and unsonicated regions of the tumor were collected and tested
for chemo-agent concentrations. Of the 5 patients, 2 had quantifiable results showing
an increase in chemo-agent concentrations in sonicated regions when compared to
unsonicated regions [25]. This mechanism should be further studied to optimize
parameters, chemotherapy session numbers, and chemotherapy doses.
Radiosensitization
Radiation therapy which uses high doses of radiation targeted at cancer cells to
destroy their DNA can be more effective when used in combination with elevated
temperatures, or hyperthermia. Prior to chemotherapy-aided BBB opening, as well
as the discovery of TMZ, a chemo-agent that can cross the BBB, radiation was the
primary source of GB treatment. Ways of sensitizing radiation therapy were heavily
investigated and inducing hyperthermia during treatment was quite promising [26].
Unfortunately, this required invasive heat probes to be placed inside the brain during
radiation therapy [26]. After advances in chemotherapy, radiosensitization using
hyperthermia was abandoned. In light of the advancements made in the field of FUS,
hyperthermia can be induced non-invasively. The hyperthermia level (41°C) [27] can
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be achieved with transcranial FUS without overheating the patient’s scalp since less
power is required for this procedure. Hyperthermia in conjunction with radiation
therapy increases perfusion and oxygenation in and around the tumor, which activates
an immune response and causes cell death [26].
Sonodynamic Therapy
SDT requires the use of a sonosensitizer (i.e., a molecule that is sensitive to ultra-
sound). The leading research of this therapy focuses on GBs since 5-aminolevulinic
acid (5-ALA) is preferentially taken up by these tumors and is converted to protopor-
phyrin IX (PpIX) within the cells, which serves as the sonosensitizer. GBs become
highly vascularized by sprouting new capillaries from pre-existing vessels, significantly
affecting the BBB within their region, which ultimately allows for GB uptake of 5-ALA
[28]. Regardless of BBB passage, 5-ALA is preferential to GB cells, which is believed
to occur due to selective uptake by an ATP-binding cassette transporter (ABCB6)
which regulates porphyrin synthesis [29–31]. Once inside GB cells, 5-ALA is converted
to fluorescent PpIX, which allows it to be regularly used in guided resection surgeries.
There are eight enzymatic steps involved in heme synthesis between the mitochondria
and cytoplasm, which include the transition of 5-ALA into PpIX [30]. CPgenIII is a
product of the fifth enzyme, uroporphyrinogen III decarboxylase, and it enters the
mitochondria from the cytoplasm to aid in the synthesis of PpIX [30]. This process
is energy-dependent, so CPgenIII movement requires ABCB6. GB cells have been
shown to possess significantly greater levels of ABCB6 than healthy cells [30–33]. The
interaction between FUS and PpIX within GB cells causes the generation of reactive
oxygen species (ROS), producing direct cytotoxic effects in the cells [34].
In an in vitro study by Sheehan et al., rat C6 and human U87 GB cells underwent
SDT and responses were analyzed using a cell viability assay and apoptosis staining.
Apoptosis staining showed a significant difference (p < 0.05) between the SDT groups
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and control groups [35]. In an in vivo study by Wu et al., C6 GB rat models underwent
SDT with single and multiple focal point treatment. Tumor volume over time and
survival rate were monitored in all groups, resulting in a significant difference between
the SDT groups and control groups ((p < 0.01) for tumor volume, (p < 0.01) for
survival rate), and even a significant difference in survival time between the single
point and multiple point treatment groups (p < 0.05) [34]. Since 5-ALA is already
regularly used in patients with GB and shows promise as a sonosensitizer, SDT should
be further explored as a treatment for GB.
Immunomodulation
Immunotherapy, which refers to treatment of a disease by activating or suppressing
the immune system, has long been investigated in the field of cancer research. The
need for tumor-specific antigens is great when it comes to cancers that frequently
recur (e.g. GB). FUS has the potential to induce such antigens that can cause an
immune response which may help fight off recurrences. Prior to the surge in cancer
research using FUS, Wissniowski et al. used radiofrequency ablation (RFA) to activate
tumor-specific T lymphocytes in a VX2 hepatoma rabbit model [36]. Once activated,
these tumor infiltrating lymphocytes were shown to recognize and kill cancer cells. Two
weeks after RFA, there was a marked activation of peripheral T cells against tumor
lysate in the treatment group while there was none in the control group. In addition,
the liver bearing the tumor underwent immunohistochemical analysis and showed a
massive increase of T-lymphocytes in and around the tumor for animals sacrificed at
the end of the study compared to those sacrificed mid-way and those in the control
group [36]. To further investigate the effects of activated antigens, den Brock et al.
used RFA in a mouse model to promote tumor antigens arising from melanoma and
tested their validity by reintroducing the cancer later on [37]. In this study, RFA was
used to destroy most of the tumor volume, so the survival rate was very high. After
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a long survival period was observed, mice were re-injected with melanoma cells to
investigate immune response. Thirty days after cancer cell reintroduction, no mice in
the control group were living, while 80% of immunotherapy-receiving mice were still
surviving [37].
This antitumor immunity effect gave promise to the possibility of collecting debris
resulting from ablation to create a tumor-specific vaccine that could be utilized to
treat first-time cancerous animals. Zhang et al. presented a study in which there was
an increase in cytotoxicity as well as a decrease in tumor volume for mice treated
with a debris vaccine, but these results were enhanced in mice that were treated with
HIFU originally and then re-challenged, indicating that an in situ vaccine specific to
the individual shows most promise for recurring types of cancer (e.g. GB) [38]. If
ablation/hyperthermia is the main cause of this immune response, this would present
an issue in GB treatment, as HIFU through the skull has already been proven to
be a challenge. Fortunately, additional studies have shown that this may not be the
case. Hu et al. explored the release of exogenous danger signals from thermal and
mechanical HIFU-treated tumor cells and how they stimulate antigen-presenting cells
(APCs) [39]. HIFU performed with parameters eliciting mechanical lysis of tumor
cells primarily caused the release of a danger signal known as heat shock protein
60 (hsp60). The release of this signal was five times greater for mechanical HIFU
than thermal HIFU. HIFU performed with parameters eliciting thermal necrosis of
tumor cells primarily caused the release of the danger signal, ATP, but the release
was stable throughout and did not progress as treatment continued. In addition, the
maturation of APCs was much more evident in mechanical HIFU than thermal HIFU.
This shows promise that FUS-induced immune response of cancer cells can be used as
a prevention for recurrence of GB.
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Focused Ultrasound Therapies for GB
From this review, it is evident that there are numerous FUS therapies with the
potential to treat GB. More research needs to be conducted for each therapy, and this







FUS is a growing technique for both noninvasive and minimally invasive surgical
(MIS) procedures, especially in neurosurgery1. It is most helpful for inoperable brain
lesions, as it can thermally ablate tissue from a distance when used at high intensities.
GBs are the most common malignant primary brain tumors, accounting for 50% of
malignant primary brain tumors [40]. GBs infiltrate healthy tissues and are therefore
difficult to surgically remove [11]. MIS FUS has the potential to lyse remaining tumor
tissue after resection, or more optimally - ablate the bulk of the tumor without having
to remove as much of the skull when compared to traditional resection surgeries.
Noninvasive ultrasound can also be used to treat brain lesions, but there are several
limitations such as the attenuation of ultrasound through the skull. To overcome this
issue, high power is required, which can result in the transducer overheating when
in contact with the patient’s scalp. As a result, researchers are investigating MIS
1The work in this chapter is reproduced from: M. Acord, T. P. Kaovasia, N. J. Gamo, T. Xiong,
E. Curry, F. Aghabaglou, K. Morri-son, B. Tyler, M. Luciano, and A. Manbachi, “Design and
Fabrication of a FocusedUltrasound Device for Minimally-Invasive Neurosurgery: Reporting a Second,
Minia-turized and MR-Compatible Prototype with Steering Capabilities,” American Society of
Mechanical Engineers, vol. 2021 Design of Medical Devices Conference, 2021.
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FUS procedures, where a small portion of the skull is removed, helping to eliminate
the attenuation caused by the skull [18–20]. However, there is much debate on how
“minimally invasive” the procedures should be.
As described in a previous study by our group [18], an ultrasound-guided focused
ultrasound (USgFUS) probe was designed with a 9mm x 32mm curved transducer
with a housing diameter ranging from 12mm-15mm to include the imaging transducer.
The first transducer design was abandoned due to lateral mode effects, which led to
issues with the transducer overheating. That transducer design was replaced with
three circular, 8mm diameter transducers, still fitting in the same housing (Design II
reported in [18]). This probe was envisioned to fit inside common MIS technology,
such as BrainPath (NICO Corporation, Indianapolis, IN), which is a trocar device
that allows atraumatic access to the brain. The largest BrainPath device, which was
13.5mm in diameter [41], was able to house the FUS transducer portion of the probe,
but not the imaging transducer portion (see Fig. 2-1).
Figure 2-1. First Generation HIFU Probe: BrainPath is a Minimally Invasive Neurosurgical
Toolkit, Envisioned to Host this Focused Ultrasound Device (reproduced with permission
from [18])
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This led to the second-generation probe (see Fig. 2-2), which will be contained
within a 10mm diameter housing, which fits within the 11mm diameter BrainPath
trocar, allowing the device to be used for MIS. In addition to size reduction, this new
design has electronic steering in the axial direction, enabling the user to reach lesions
at various distances from the probe within the brain, without manual movement of
the probe. Lastly, the new prototype is designed to be MR-compatible, in order to
provide ease-of-use to clinicians, who may be trained for MR-guided procedures, and
may find ultrasound image-guidance difficult to interpret during an involved surgery.
Figure 2-2. Minimally Invasive High Intensity Focused Ultrasound Procedure Schematic,




The advantages of reducing the size of the probe are two-fold: the procedure
is less invasive and the full probe can fit into the BrainPath trocar. The first goal
of the second-generation probe design was to create an MR-compatible probe that
can be used in procedures requiring MRI guidance. Designed and fabricated by
Sonic Concepts Inc. (Bothell, WA), the H-284 model is an MR-safe, 1.2MHz HIFU
transducer with +/- 50% bandwidth. The transducer is contained in plastic housing
as seen in Fig. 2-3, making the entire probe MR-compatible.
Figure 2-3. Transducer Stack and MR-Safe Housing (reproduced with permission from
[42])
In terms of size, the transducer has a 45mm radius of curvature (ROC) with a total
7mm x 32mm rectangular aperture (see Fig. 2-4). Piezo-composite pillars (see Fig.
2-5) are hypothesized to reduce the lateral mode effects seen in the first-generation
probe Design I. This new approach should provide optimal performance without
overheating the transducer.
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Figure 2-4. (A) Second Generation and (B) First Generation Probe Designs (reproduced
with permission from [42])
Figure 2-5. Piezo-Composite Pillars Used to Reduce Lateral Mode Effects (reproduced
with permission from [42])
The other main improvement of the second-generation probe is its focal point
steering capability. The focal point can be electronically steered along the axial
dimension through the use of time delays in the activation of different array elements,
which results in phase differences between the array elements. The total aperture of
this transducer is divided into three elements (see Fig. 2-6).
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Figure 2-6. Second Generation Transducer Design with Three Elements Allowing for
Electronic Steering (reproduced with permission from [42])
PiezoCAD Simulations
FUS transducers are electronically interfaced to a signal generator and power
source. To ensure maximum power transfer between the source and the transducer (as
well as its subsequent conversion to acoustic power), both impedances should be the
same [43]. Therefore, an impedance-matching circuit is used. Commercially available
sources operate at an equivalent (Thevenin) output impedance of 50 Ω, which means
the transducer should be matched to have an input impedance of 50 Ω [44].
To ensure that the transducer would be designed in such a way as to possess an
impedance of 50 Ω, PiezoCAD simulations were utilized to model the transducer. The
transducer consists of a piezoelectric crystal, with both ends of the crystal coated
in a conductive material such as sputtered chromium-gold. With this design, the
transducer behaves like a capacitor whose impedance is frequency-dependent. The
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crystal converts electrical pulses to acoustic waves and is designed to operate around a
central frequency [45]. This frequency affects the electrical impedance of the transducer,
which in turn affects the transmitted and converted power. The PiezoCAD software,
designed by Sonic Concepts, was used to study the effect of varying the frequency on
the magnitude and associated phase angle of transducer impedance, as well as the
transmitted transfer function (ratio of the acoustic output power to the electric power
provided by the source) for each element [46]. These effects were also investigated for
a parallel combination of all three elements.
The parameters and subsequent values of the electrical matching network for each
of these four cases are listed in Table 2-I. The series inductance (L) and resistance (R),
shunt inductance (L), and transformer serve as the circuit to match the impedance
of the source to that of the load (transducer elements). The inductive reactance
(XL) varies with frequency (f): XL= j2πfL. Therefore, the resistance and inductance
values are selected to match the impedance at the center frequency. The coaxial cable
connects the source to the transducer elements. For maximum power to be transferred
over the cable, from the source to load, the impedance of this cable should match that
of the source and load (50 Ω).
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Table 2-I. PiezoCAD Simulation Parameters (reproduced with permission from [42])
Transducer Element Parameter Value
Element 1
Series L 10 µH
Series R 1 Ω
Coaxial Cable 50 Ω, 2 m, 28 dB/km at 1MHz
Shunt L 66.31 µH
Transformers 1:3.84 turns
Element 2
Series L 10 µH
Series R 1 Ω
Coaxial Cable 50 Ω, 2 m, 28 dB/km at 1MHz
Shunt L 66.31 µH
Transformers 1:3.84 turns
Element 3
Series L 10 µH
Series R 1 Ω
Coaxial Cable 50 Ω, 2 m, 28 dB/km at 1MHz
Shunt L 53 µH
Transformers 1:2.2 turns
Elements in Parallel
Series L 10 µH
Series R 1 Ω
Coaxial Cable 50 Ω, 2 m, 28 dB/km at 1MHz
Shunt L 110 µH
Transformers 1:1.58 turns
Field II Ultrasound Simulations
To gain an understanding of the focusing and steering capabilities for this trans-
ducer, ultrasound fields showing focal point location and pressure were simulated using
the Field II Ultrasound Simulation Program [47]. The program uses the Tupholme-
Stepanishen method, which can be used to calculate pulsed, continuous-wave, and
pulse-echo ultrasound fields. The calculation is done by dividing the surface into small
rectangles and summing their response [48].
The purpose of this simulation was to determine the phase angle limits, and thus,
the focal point location limits. The multi-element transducer presented here allows
for phase (or time) delays, measured in radians, between the elements which will
shift the focal point to different distances away from the probe. Various phase delays
19
were simulated to examine the furthest and closest possible focal point locations
without having any unwanted effects, such as grating lobes, which result from energy
that spreads out from the transducer at angles other than the primary path. This
will help determine the depths in the brain at which lesions could potentially be
treated. It is important to note that these simulations are done in a homogenous
medium, such as blood or water, and hence will not be fully representative of the
non-homogenous tissues of the white and gray matter. Despite this assumption, the
results of these simulations can provide a general understanding of the focusing and
steering capabilities of the new transducer design.
Results and Discussion
PiezoCAD Simulations
Due to the capacitive nature of the transducer, its impedance depends on the
frequency of the electrical signal. Fig. 2-7A shows the variation of both the magnitude
and phase angle of the impedance with frequency. The red line shows the impedance
(50 Ω with a phase angle of zero) of the transducer at its center frequency (1.2MHz).
As the impedance of the transducer varies, its impedance can get mismatched
with the power source. Due to this mismatch, the transfer function may decrease;
however, the impedance and the corresponding transfer function at the operating
center frequency were the sole focus of this analysis. Figs. 2-7B, 2-8, 2-9, and 2-10
show the variation of the transfer function with frequency, with the red line passing
through the center frequency.
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Figure 2-7. (A) Impedance Curve for Element 3. (B) Transmitted Transfer Function
Curve for Element 3 (reproduced with permission from [42])
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Figure 2-8. Transmitted Transfer Function Curve for Element 2 (reproduced with
permission from [42])
Figure 2-9. Transmitted Transfer Function Curve for Element 1 (reproduced with
permission from [42])
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Figure 2-10. Transmitted Transfer Function Curve for all Elements in Parallel (reproduced
with permission from [42])
Table 2-II shows the magnitude and phase angle of the impedance for element 3
and the transfer function for elements 1, 2, 3, as well as the parallel combination of
them at center frequency. Consistency in the magnitude and phase of the transfer
function were seen in each case, which demonstrates the reliable operation of the
probe.
Table 2-II. PiezoCAD Simulation Results
Transducer Element Parameter Value
Element 1 Impedance 49.919 Ω | -0.569°Transmitted Transfer Function 6.116 kPa/V | 101.684 °
Element 2 Transmitted Transfer Function 6.245 kPa/V | 104.472°
Element 3 Transmitted Transfer Function 6.538 kPa/V | 112.695°
Elements in Parallel Transmitted Transfer Function 6.719 kPa/V | 128.944°
Field II Ultrasound Simulations
There is a great need for electronic steering of the focal point when treating brain
tumors, the dimensions of which are within the centimeter range. The focal point
may be 2-5 mm in length, but unfortunately, GB tumors may have a cross-sectional
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area of 1100 mm2 [49]. For HIFU to be effective and remain minimally invasive, the
probe must have the capability to move the focal point to treat larger tumors. A
transducer of this size and curvature will create a focal point about 4.1-4.5 cm away.
By changing the phase angle, and thus, creating time differences in the firing order of
the three elements, the focal point can be moved closer or farther from the transducer.
Various angles were tested, and acceptable limits were found to be -2.25 radians and
0.75 radians. Table 2-III shows these angles and their respective location information.
Table 2-III. (Acceptable Phase Angle Limits and Their Respective Focal Point Locations
reproduced with permission from [42])
Phase Difference (in radians) -2.25 0 0.75
Phase Difference (in degrees) -128.9° 0° 49.9°
Zmax 33 42 46
Figs. 2-11 and 2-12 show two different perspectives of the focal point simulations
for each phase angle. Here, grating lobes were shown to start appearing on the
limiting phase angles. One can see that no phase angle produced a clear, straight,
non-deviating energy path toward the focal point. However, the other limiting phase
angles produced grating lobes that could result in unwanted and potentially harmful
high-pressure points before the focal point. Employing phase angles outside of these
limits could cause extra focal points to be created in healthy tissue, which could be
harmful.
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Figure 2-11. (A) Focal Point Profile (YZ View) for a Phase Angle of 0.75 Radians, (B)
Focal Point Profile (YZ View) for a Phase Angle of 0 Radians, and (C) Focal Point Profile
(YZ View) for a Phase Angle of -2.25 Radians (reproduced with permission from [42])
25
Figure 2-12. (A) Focal Point Profile (XZ View) for a Phase Angle of 0.75 Radians, (B)
Focal Point Profile (XZ View) for a Phase Angle of 0 Radians, and (C) Focal Point Profile
(XZ View) for a Phase Angle of -2.25 Radians (reproduced with permission from [42])
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Potential Risks
With any brain surgery, minimally-invasive or noninvasive, there are always po-
tential risks. The probe user should always inspect the transducer face and bonding
for any damage before performing surgery, as damage to these may pose an electrical
shock hazard. The surgeon should never submerge the probe past the handle, as the
cord extending from the probe is not meant for invasive procedures. When performing
MIS, surgeons have to perform a craniotomy or burr hole. Fortunately, they only
need to remove a small portion of the skull the size of the BrainPath trocar, contrary
to typical resection surgeries. Though this is still invasive, the need for thermal
ablation can outweigh the risks for treating certain lesions like brain tumors. Without
a craniotomy, there is far too much ultrasound attenuation through the skull, resulting
in overheating and possible danger to the patient [18].
Conclusion
In this study, the design and fabrication of a FUS device were described in such a
way that allows for miniaturization, steering of the focal point, and MR-compatibility.
The first-generation design consisted of three circular, 8mm diameter transducers,
fitting into a 12mm diameter housing, along with an adjacent imaging transducer,
which extended the housing diameter to 15mm. The therapeutic transducers in the
first-generation design were capable of fitting into a BrainPath trocar with a 13.5mm
diameter, but the imaging transducer was unable to fit within the trocar. The second-
generation transducer, discussed here, consisted of a 7mm x 32mm curved transducer,
that fit into a 10mm housing. This probe is capable of fitting into a BrainPath trocar
with an 11mm in diameter. Three elements were incorporated into the therapeutic
transducer that allows for axial steering when time delays are introduced. The focus
can be positioned approximately 4.1-4.5cm away from the transducer. This probe was
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also designed to be MR-compatible, affording surgeons the ability to use the device
with MRI guidance. The miniaturization enables MIS approaches for the treatment of
brain lesions, while the steering capabilities of the focal point allow for the treatment
of lesions of various sizes. MR-compatibility would pave the path for FUS treatments
under MR-guidance. The MIS technique has the potential to allow for effective thermal




guided Focused Ultrasound System
Introduction
System Basics
The RK-300 developed by FUS Instruments (Toronto, Canada) is a small animal
research FUS device [50]. It is compatible with all Bruker Biospec horizontal bore
MRI systems ranging from 3 to 9.4 Tesla. With its non-magnetic motors, the RK-300
is capable of 2-axis positioning allowing the user to select a sonication target anywhere
within the 2D plane. The calibrated FUS transducer works for two frequencies: 1.106
MHz and 3.164 MHz. Sonications can be continuous-wave, pulsed-wave, and even
planned and performed in a serial fashion. The image-based treatment planning
software allows for registration of the focus and knowledge of the exact focus location
within the animal or phantom being treated.
Potential Applications
The RK-300 has a number of potential applications that could be used for GB
research, such as thermal ablation, non-invasive hyperthermia, BBB opening, SDT,
etc. An early prototype of this system was used in a study mentioned previously,
where C6 GB rat models were used to study the effects of SDT [34].
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Phantom Study Overview
Given the numerous potential applications of the RK-300, it was important to
test and confirm its primary functions: focus generation, focal point planning, and
MR-guidance. A phantom study was designed to optimize focus finding, sample
preparation, target planning, and real time MR imaging of water movement resulting
from focus formation in the phantom.
Materials and Methods
Hardware, Software, and Components
The hardware shown in Fig. 3-1 consists of front-end electronics (i.e., the MR-safe
arm which houses the transducer and mechanical motors) and back-end electronics
(i.e., the controller and processor, function generator, power source, and RF power
amplifier). The software shown in Fig. 3-2 can be accessed through the computer
provided and serves as a user interface (UI) that allows for focus finding and treatment
planning. There are several additional components that serve as tools for varying
applications of the system. The primary components used in this study are shown
in Fig. 3-3: the plastic sledge that covers the transducer section of the arm, the
membrane cuboid that provides a sonolucent barrier between the water and sample,
the additional water bath, and focal marker for focus finding.
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Figure 3-1. Front-end and Back-end Electronics. (A) MR-Safe arm housing transducer
and motors. (B) Controller and Processor, Function Generator, Power Source, and RF
Power Amplifier.
Figure 3-2. RK-300 Software User Interface
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Figure 3-3. Components. (A) Plastic Sledge, (B) Membrane Cuboid, (C) Water Bath,
(D) Focal Marker.
Registering the Focus
The space around the transducer was filled with degassed water and the plastic
sledge was placed over the transducer section of the arm. Next, the membrane cuboid
was placed over the transducer and water, ensuring no air bubbles. A small amount of
water was deposited over the membrane cuboid and the water bath was placed on top,
again ensuring no air bubbles. The bath was then partially filled with water for the
guided focus finding. Within the initialization tab of the software, there is a "Guided
Focus Finding" section that allows for sonication at 1 Watt in order for the user to
see the transducer produce a focus creating a fountain in the water bath. By raising
or lowering the water level in the water bath, the fountain can be sharpened. After
the fountain was as sharp as possible, the focal marker was placed over the bath with
the fountain at the center of the column. The marker was then taped down and the
water bath filled almost completely. Next, the arm was placed into the MRI for T1
weighted FLASH scans. The resultant coronal scans were transferred to the RK-300
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software in order to set the transducer position to home (0, 0, 0).
Figure 3-4. Focus Finding. (Step 1) Place plastic sledge over transducer section of the
arm. (Step 2) Fill transducer cavity with degassed water. (Step 3) Place membrane cuboid
over the transducer. (Step 4) Place water bath over membrane cuboid and add water.
(Step 5) Sonicate and raise/lower the water level to sharpen fountain. (Step 6) Place
focal marker.
Figure 3-5. Focus Registration. (A) Setting the focus to the center of the column. (B)
Focus set to center of column.
The Phantom
The phantom used in this study was a white solid-water tissue-mimicking phantom
(CIRS, Norfolk, VA). The phantom was initially prepared by removing the water bath,
depositing a layer of degassed ultrasound gel over the membrane cuboid, and securing
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the phantom to the membrane. Unfortunately, this led to bubbles formed when the
gel folded into itself. Bubbles were resolved by replacing the water bath and adding
the phantom in water (see Fig. 3-6). The RK-300 arm with phantom secured was
then returned to the MRI for T1 weighted FLASH scans (see Fig. 3-7).
Figure 3-6. Solid-water tissue-mimicking phantom from CIRS, Norfold, VA.




Initially, the coronal scans were transferred to the RK-300 software for focal plane
determination. The middle coronal slice (showing the middle of the transducer) was
selected. Following the Pythagorean theorem (see Fig. 3-8A), the focal plane was
calculated. The height of the focal plane (15.61mm) was subtracted from the blue
focus point’s corresponding p-value, found at the bottom of the window in light
blue, to determine the slice value (p-value) of the axial view. Axial scans were then
transferred to the software and the correct focal point slice was used for sonication
target planning (see Fig. 3-8B). The focus could be moved to a desired location in
the fixed z plane, as shown in Fig. 3-8C.
Sonication
In order to generate a focus that could be viewed with real-time MRI, 2 Watts
of power were used with a frequency of 1.106 MHz for continuous sonication. The
sonication time was set to 15 seconds and the wait time was set to 10 seconds. 15 T1
weighted FLASH scans of the axial slice being sonicated were taken in sequence to
capture the water movement created by focus generation. Each image was acquired
over 5 seconds. Two images were acquired and then sonication began for 15 seconds,
capturing about 3 images during this time.
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Figure 3-8. Target Selection. (A) Finding the correct focal plane in the axial view and
corresponding slice number. (B) Corresponding coronal slice. (C) Selecting the desired
target in the coronal plane.
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Results and Discussion
T1 weighted FLASH single slice scans acquired during sonication revealed a focus
generation (see Fig. 3-9). The phantom began at the hyper-intense/hypo-intense
interface with the phantom being hypo-intense. The focus (hyper-intense cone) did not
go into the phantom as expected. This was likely due to the phantom partially floating
in the water bath rather than being flush with its bottom surface. The light gray
line that cuts the middle of the cone was the membrane cuboid. It was understood
that the focus was fully formed due to the approximate width and height of the focus
ellipsoid measured during post-processing. The width and height of the focal spot
according to FUS Instruments specifications were 1.7 mm and 9.3 mm, respectively.
Post-processing measurements of the narrowest width and shortest height were found
to be 2.52 mm and 10.14 mm, respectively, indicating the focus was fully formed below
the phantom. In the next study, the phantom should be pressed down securely and
kept flush with the bottom of the water bath.
Figure 3-9. MRI Scan of focus generation during sonication.
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Conclusion
Through this phantom study, functionality of the RK-300 was confirmed. The
guided focus finding procedure allowed for the focus to be registered at the home
position. Treatment planning was successful in that the x,y planes selected for
sonication corresponded to the correct axial slice used for real-time MRI. A clear focal
point of appropriate size, defined by the manufacturer, was visible with real-time MRI.
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Chapter 4




Focused Ultrasound in the Brain: The Unknowns
FUS in the brain is only FDA approved for the treatment of essential tremor [51].
Part of this is due to the unknown effects of the technology and the lack of ability to
monitor certain biomarkers during treatment. A major concern for HIFU treatments
in the brain is temperature change. MR thermometry is currently what is used to
track temperature changes, but this is not a real-time measurement. FLASH gradient
echo sequences can be used for capturing real-time images and temperature maps are
then processed after imaging [34], delaying the temperature information. If any type
of craniotomy is performed, such as for MIS, temperature probes could be used for
real-time monitoring, but this adds a more invasive component to the already invasive
procedure. Therefore, in order to incorporate HIFU into standard clinical treatment,
there is great need for a minimal to non-invasive real-time temperature monitoring
method that can be used during FUS therapies in the brain.
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Fiber Optics
Optical fibers are thin, flexible, transparent glass fibers that transmit light from
one end of the fiber to the other. They are typically comprised of a core with a high
refractive index and surrounded by transparent cladding with a lower refractive index.
Light particles (photons) remain trapped inside the core and travel along the fiber
due to the phenomenon of total internal reflection (TIR). TIR occurs when photons in
one medium strike the boundary in an oblique fashion with a second external medium,
in which light travels faster than in the first internal medium.
Figure 4-1. Principles of fiber optics. Light remains trapped in the core and travels along
the fiber due to TIR.
Fiber optic temperature sensors operate on the principle based on the temperature
dependence band gap of gallium arsenide (GaAS) crystal. The crystal is fixed on
the sensing tip of the fiber and behaves as a temperature sensitive filter, where the
crystal absorbs light at certain wavelengths and reflects light at other wavelengths
depending on the temperature of the medium it’s in. The light reflected back is sent to
a miniature spectrometer, which provides a spectrum based on the temperature [52].
More specifically, the system is recording the photo energy that is sufficient enough
to excite an electron from the valence band to the conduction band of the crystal.
That required amount of energy is referred to as the band-gap energy. The transition
wavelength that separates the absorbed and reflected wavelengths is determined by
the crystal’s band-gap energy. [53].
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Minimally-Invasive Real-Time Temperature Monitoring
The beauty of fiber optics is that it provides real-time temperature measurements
and is thin and flexible, making insertion into the brain, quite simple. For minimally-
invasive FUS thermal ablation with the HIFU probe, a fiber optic temperature sensor
could be placed inside a catheter with a needle tip and positioned in the designated
area through the already exposed brain tissue. For non-invasive FUS procedures in
the brain, a fiber optic temperature sensor could be introduced into the brain via a
small burr hole or through the nostril.
Materials and Methods
Selection of Fiber Optic Temperature Sensor
Fiber optics have a wide range of applications throughout several industries
including medical, environmental, chemical, microwave and radio-frequency, electrical,
etc. A fiber optic temperature sensor that could be used in the CNS would have
several requirements:
• Compatible with ethylene oxide sterilization for repetitive pre-clinical testing
• Able to withstand epoxy adhesive coating in order to secure the fiber to a
catheter for insertion
• A small bending radius that would not cause significant signal loss, as the fiber
may need to be fed through the nostril and into the brain at various angles
• A measurement range of 35-65°C to account for values of human body tempera-
ture up to temperatures generated by thermal ablation
• A resolution of at least 0.2°C to monitor the slightest increase in temperature
to ensure safety of the patient
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• Able to maintain temperature readings within the specified resolution for at
least 24 hours
As part of this study, selection of an appropriate fiber optic temperature sensor
was determined by extensive product research. Three vendors were selected and
their products compared. In Table 4-I, it can be seen that the FISO sensor met
all of the requirements, as well as had the smallest diameter - a key component for
insertion into the CNS via varying pathways. As a result, the FISO sensor (Model
#: THR-NS-1165E), shown in Fig. 4-2 was acquired and all experimental analyses
discussed here were conducted with the FISO sensor.
Table 4-I. Temperature Sensor Comparison
Parameter OpSens [54] Rugged Monitoring[55] FISO [56]
Outer Diameter




0.56 mm —- 0.310 mm
Fiber Length 1.5 m 2 m 2m
Polyimide Tubing
Length 0.9 m —- 1.8 m
Operating Temper-
ature Range 20-85°C -200 to 250°C 10-90°C
Resolution 0.01°C 0.1°C 0.1°C
Bending Radius 10 mm 400 mm 17 mm
Sterilization
Method Ethylene Oxide Autoclave Ethylene Oxide
Epoxy Coating Yes, on fiber butnot on sensor tip
Yes, on fiber but not
on sensor tip
Yes, on fiber but
not on sensor tip
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Figure 4-2. FISO Temperature Sensor Schematic (reproduced with permission from [56]).
FISO Materials
The FISO sensor selected was ordered with custom modifications. Rather than
typical long insulation covering most of the fiber (which would increase the diameter of
the cable), polyimide tubing was placed over the fiber from the connector to almost the
sensor tip. The signal conditioner used for this temperature sensor was the SPC-HR
reading module designed for research and original equipment manufacturer (OEM)
applications and is shown in Fig. 4-3. It consisted of two channels and was cable of
sampling at a rate of 125 Hz. Included with the system was the Evolution Software
that allowed for configuration and control of reading the sensor, simple monitoring
and real-time graphing, as well as exporting of data into multiple formats.
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Figure 4-3. (A) FISO Signal Conditioner and (B) Dimensions (reproduced with permission
from [56]).
Zero Drift
Zero drift testing verifies the requirement of the temperature sensor to maintain
readings within the specified resolution for at least 24 hours. Testing was carried out
in a 660 ml water bath held at 37°C for 24 hours. The fiber optic temperature sensor
was inserted in a small hole through the water bath lid and secured outside so that
the tip could free float but remain clear of the walls and heating element.
Stability of Measurement
The purpose of testing for stability of temperature sensing, is to ensure that other
environmental factors do not affect stability of the sensing. Another component of
the environment can be varied to visualize unwanted effects. For this test, pressure
was chosen. The setup is shown in Fig. 4-3, where a hydrostatic water column was
placed inside a temperature-controlled water bath. Temperature was recorded for 30
seconds while the water bath was held at 42°C and the absolute pressure was set to
7.356 mmHg by keeping the water at a height of 10 cm in the column. Temperature
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was recorded again for 30 seconds while the water bath remained set at 42°C and the
pressure was increased to 13.976 mmHg by raising the water level in the column to 19
cm.
Figure 4-4. Stability of Measurement Test Setup. Water bath kept at 37°C with a
hydrostatic water column.
Accuracy
Accuracy testing was carried out in a 660 ml water bath. Temperature was varied
between 24-42°C by increments of 2°C. For each temperature point, the fiber optic
sensor and two reference sensors measured the water temperature for 5 minutes. The
reference sensors’ temperature was manually recorded every 30 seconds. This was
repeated 3 times for each temperature point. Two Fahrenheit negative temperature
coefficient (NTC) temperature sensors, which measure increasing temperature by
decreasing resistance, were used as the reference sensors [57].
Bend Radius
To ensure that the sensor remained functional and had no significant loss of
signal under various bend radii imposed by the surgeon on the integrated catheter,
temperature recording was conducted at bend radii of 8.5 mm, 17 mm, and 30 mm




The potential drift of the temperature sensor needed to be evaluated given that
many FUS procedures can last on the order of hours. This is particularly important
for thermal ablation procedures that need real-time accurate temperature monitoring.
Fig. 4-4 shows the results of the 24 hour zero drift test of the fiber optic temperature
sensor. The sensor was kept in a temperature-controlled water bath held at 37°C. One
can see that there was no significant drift from this temperature over a 24 hour period
of time. Further, the mean and standard deviation of the readings were 36.40°C and
+/- 0.22, respectively. Temperatures in the thermal ablation range should be tested
next.
Figure 4-5. Zero Drift Testing Results
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Stability of Measurement
During complex procedures, it is important to ensure other environmental variables
do not have significant effect on temperature sensing. Pressure variation was used to
observe any effects on temperature measurement, although more variables should be
varied in future testing. Results of temperature sensor stability are shown in Fig. 4-5.
The different pressures did not cause any significant effect on temperature sensing.
Even at the greatest gap in readings (between 0 and 10 seconds), the difference was no
more than 0.2°C, which equates to the desired resolution requirement for the sensor.
Figure 4-6. Stability of Measurement Testing Results
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Accuracy
The FISO temperature sensor chosen was manufactured to have a sensing range of
10-90°C. This covers human body temperature, as well as above and below, which
will be sufficient for all types of FUS procedures in the CNS. Since a primary concern
of thermal ablation procedures is rising temperature, it is important to ensure the
accuracy of the sensor as the medium in which it’s in heats. Here, accuracy was tested
by varying the water bath temperature between 24-42°C. Two reference sensors were
used in conjunction with the fiber optic sensor to gauge its accuracy. Four accuracy
temperature plots are shown in Fig. 4-6. At the lower temperatures (26°C and 36°C),
the fiber optic sensor remained stable within a 0.2°C variation and recorded quite
similar to the reference sensors. At higher temperatures (40°C and 42°C), the fiber
optic sensor remained quite stable within a 0.2°C variation, but differed from the
reference sensors. This is believed to be due to the reference sensors only having a
resolution of 0.1°F between 0-100°F. Higher temperatures above 40 °C are equivalent
to 100+°F values, meaning there was only a 1°F resolution during these tests. These
tests will be repeated with a platinum resistance sensor as the reference sensor. Higher
temperatures in the thermal ablation range will also be tested.
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Figure 4-7. Accuracy Testing Results
Bend Radius
Due to the principle of fiber optics in which light travels along the core via TIR,
bending the fiber can cause signal loss or incorrect readings. By bending the sensor,
light will reflect off the cladding in a different pattern than expected. In order to use
a fiber optic sensor within complex FUS procedures, it may need to be routed into
the CNS via various pathways that may cause bending. Values at, above, and below
the FISO recommended bend radius of 17 mm were tested to determine if bending
would cause any significant signal loss and/or incorrect readings. Fig. 4-7 shows the
results of the bend radius test in which bend radii of 30 mm, 17 mm, and 8.5 mm
were imposed on the fiber while the sensor recorded values for 1 hour in a 37°C water
bath. They are in agreement with one another, suggesting that small coils can be
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made with this fiber without any signal loss or incorrect readings. Future testing will
be conducted in which multiple coils are imposed over a longer recording period.
Figure 4-8. Bend Radius Testing Results
Conclusion
The FISO fiber optic temperature sensor presented here has met all requirements
necessary for measuring temperature throughout the CNS during FUS procedures
based on preliminary testing. Further testing will be conducted to re-evaluate accuracy
and bend radius findings, as well as to ensure stability of measurement when exposed to
varying environmental factors. Fiber optic sensors are capable of real-time temperature
measurements and are thin and flexible, making insertion into the brain, quite simple.
For minimally-invasive FUS thermal ablation with the HIFU probe, a fiber optic
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temperature sensor could be placed inside a catheter with a needle tip and positioned
in the designated area through the already exposed brain tissue. For non-invasive
FUS procedures in the brain, a fiber optic temperature sensor could be introduced
into the brain via a small burr hole or through the nostril. The next steps will be to





GBs are the most common malignant primary brain tumors, accounting for 50%
of malignant primary brain tumors and 15% of all central nervous system tumors [3].
GBs are aggressive, invasive, and result in the shortest survival rate among malignant
brain tumors. There are numerous FUS therapies with the potential to treat GB.
More research needs to be conducted for each therapy, and this thesis has explored
devices that can be used for most, if not all of them.
The minimally invasive HIFU probe has been designed and fabricated in a way
that allows for miniaturization, steering of the focal point, and MR-compatibility. It
consisted of a 7mm x 32mm curved transducer, that fit into a 10mm housing. It is
capable of fitting into a BrainPath trocar with a diameter of 11mm. Three elements
were incorporated into the therapeutic transducer that allows for axial steering when
time delays are introduced. The focus can be positioned approximately 4.1-4.5cm away
from the transducer. This probe was also designed to be MR-compatible, affording
surgeons the ability to use the device with MRI guidance. The miniaturization enables
minimally invasive approaches for the treatment of brain lesions, while the steering
capabilities of the focal point allow for the treatment of lesions of various sizes. MR-
compatibility would pave the path for FUS treatments under MR-guidance. The
minimally invasive technique will allow for effective thermal ablation of GB in one
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procedure. Although it was designed with thermal ablation in mind, the HIFU probe
if coupled properly, has the capability of performing transcranial FUS for less intense
therapies (i.e., SDT, BBB opening, radiosensitization, etc.)
Through the phantom study, functionality of the RK-300 was confirmed. The
guided focus finding procedure allowed for the focus to be registered at the home
position. Treatment planning was successful in that the x,y planes selected for
sonication corresponded to the correct axial slice used for real-time MRI. A clear focal
point of appropriate size, defined by the manufacturer, was visible with real-time
MRI. Providing optimal results in future testing, the RK-300 can be used for several
effective GB treatments as well.
The FISO fiber optic temperature sensor presented here has met all of the re-
quirements necessary for measuring temperature throughout the CNS during FUS
procedures. It is capable of real-time temperature measurements and is thin and
flexible, making insertion into the brain straightforward. For minimally-invasive FUS
thermal ablation with the HIFU probe, a fiber optic temperature sensor could be
placed inside a catheter with a needle tip and positioned in the designed area through
the already exposed brain tissue. For non-invasive FUS procedures in the brain, a
fiber optic temperature sensor could be introduced into the brain via a small burr
hole or through the nostril. Providing that most types of GB therapies and treatment
procedures are lengthy and involve thermal effects, real-time temperature monitoring
will serve as a safety mechanism.
Limitations
The HIFU probe presented here will depend on imaging modalities other than
ultrasound for guidance. Although designed to be MR-compatible, testing for the
probe is still underway to ensure that the strong magnetic fields do not cause heating
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of any elements or interference in the performance of the device. Also, the frequency
of MRI scans required to guide and monitor the therapy might pose a limitation. The
artifact (if any) that the probe would produce in an image would need to be considered.
In terms of other imaging modalities, such as CT, additional testing would need to be
completed to not only ensure that the probe does not cause excessive artifact, but also
whether the probe can withstand X-ray exposure. In addition to imaging limitations,
this probe cannot be tested on small animals, since it is designed to fit within the
brain of a human. Large animal studies might be possible.
Unfortunately, the generation of a focus within a phantom could not be confirmed
with the RK-300. As previously mentioned, the phantom could not be easily coupled
to the membrane cuboid with gel, due to the presence of bubbles. The gel was
centrifuged to reduce bubbles, but ultimately more bubbles were formed when the gel
was expelled and created folds over itself. This led to the phantom being placed inside
a water bath, in which it floated slightly. The phantom should have been pressed
down firmly and secured to the base of the water bath.
With the goal of using the fiber optic temperature sensor for monitoring of FUS
procedures, testing needs to be done to ensure that FUS will not cause any unwanted
effects on the fiber. In addition, the water column and bath used for stability of
measurement testing is a weaker version of a traditional pressure chamber. A chamber
specifically designed for this testing would be best for further work.
Future Directions
The beauty of FUS is that it has endless potential for applications of GB treatment.
In turn, this presents the mountain of research that needs to be conducted in order to
incorporate this technique into the clinical setting. Preliminary data of a minimally
invasive HIFU probe shows promising functionality, but further testing of ablation
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capabilities and confirmation of focal steering is still needed. In addition, testing must
be conducted in cadavers and large animal models. Visualization of the focus using the
RK-300 with MRI indicates the system is fully capable of meeting research needs, but
a BBB opening in an animal could serve as confirmation of FUS penetration through
the skull before complete animal studies commence. Bench top testing of a fiber optic
temperature sensor shows promising results, but animal testing with reference sensors
and MR thermometry are needed to confirm its reliable usage in FUS procedures.
At Johns Hopkins, in vitro and in vivo SDT studies are currently underway and
will be the next experiments conducted with the RK-300. In vitro studies will confirm
the preferential uptake of 5-ALA in human GB cells, access ROS production from
SDT, and examine ROS effects on neighboring healthy cells. In vivo studies will
confirm repeatability of treatment parameters from the Wu et al. study [34], as well
as explore the effect of multiple SDT treatments for the same animals, with the goal
of complete tumor destruction.
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Table I-I. MRI Parameters
Parameter Focus Registration Phantom Registration Sonication
Scan Type T1-weighted FLASH T1-weighted FLASH T1-weighted FLASH
Slice Thickness 1 mm 1 mm 1 mm
Number of Slices 5-6 10-12 1
Gap Between Slices 0 mm 0 mm N/A
FOV 60x60 mm 60x60 mm 70x70 mm
Echo Time (TE) 2.1 ms 2.1 ms 20 ms
Repetition Time (TR) 120 ms 128 ms 39 ms
Acquisition Matrix 200x200 pixels 200x200 pixels 128x128 pixels
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Therapeutic Ultrasound and Noninvasive Therapies Laboratory (Vlaisavljevich Lab), Virginia Tech                                             Blacksburg, VA    
• Optimized focused ultrasound parameters for DNA extraction of salmon tissue and timber 
• Performed traditional DNA extraction for comparison 
• Analyzed data for future development of portable focused ultrasound DNA extraction device   
Chemical Engineering Intern (Glycolic Acid Production)                               (May 2018 – Aug 2018) 
The Chemours Company                                                                                                     Bell, WV 
• Led project to install ventilation and fume capture in acid drum plant 
• Created standard operating conditions (SOC) for heat trace alarms 
• Calculated throughput capacity for all process equipment 
• Inspected files, ensuring they had all required information as part of the Mechanical Quality Assurance Initiative 
Undergraduate Researcher                                                                                                                                                   (Oct 2017 – May 2018)                                                                                                                  
Institute for Critical Technology and Applied Science (ICTAS), Virginia Tech             Blacksburg, VA 
Research Experience for Undergraduates (REU) Grant to study the structure, function, and mimicry of biological surfaces                                                                                                         
• Performed cell culturing and plating on capillary-like surfaces 
• Investigated properties of these surfaces using a quartz crystal microbalance with fibronectin coating 
• First author poster presenter at the Student Experiential Learning Conference 
Undergraduate Researcher                                                                                                                                                   (Sept 2016 – Dec 2017)                                                                                                                  
Lee Laboratory, Virginia Tech                                                            Blacksburg, VA    
Drug Delivery, Autism Spectrum Disorder (ASD), and Lupus Studies 
• Quantified behavioural and social data of ASD test subjects 
• Prepared dihydrothidium (DHE) stains of ASD brain samples and observed reactive oxidative stress present 
• Assisted with tissue collection from ASD and Lupus test subjects 
• Co-author poster presentor for School of Biomedical Engineering and Sciences Symposium  
PROJECTS 
Materal Health Monitor                                                                                                                         (Sept 2019 – Dec 2019) 
• Researched main causes of materal mortality 
• Designed a wearable health monitor to measure heart rate, temperature, and blood pressure 
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• Wrote Arduino algorithm to measure heart rate and temperature 
• Assembled and integrated all electrical components into a prototype 
Communication for Quadriplegics                                                                                                                (Nov 2019) 
• Wrote an Arduino algorithm to implement text based on inputs from joystick sensors 
• Assembled and integrated all electrical components into the system 
REM Sleep Eye Mask Tracker                                                              (Oct 2019) 
• Identified piezo resistors as the sensors to be used for detection of eye movement through eyelids 
• Assembled and integrated all electrical components into the system 
Removal of Carbon Dioxide from the Atmosphere                                                (Jan 2018 – May 2018) 
Senior Design Project with MATRIC in Charleston, WV 
• Calculated 1% of how much CO2 must be captured to maintain a constant atmospheric pressure worldwide 
• Researched and developed a solid adsorption with temperature swing process to remove CO2 
• Designed and simulated a chemical plant for this process 
PUBLICATIONS 
• Molly Acord, Tarana Kaovasia, Nao Gamo, Tim Xiong, Kyle Morrison, Betty Tyler, Mark Luciano and Amir Manbachi, ‘Design and 
Fabribation of a Focused Ultrasound Device for Minimally-Invasive Neurosurgery: Reporting a Second, Miniaturized and MR-
Compatible Prototype with Steering Capabilities’, Design of Medical Devices Conference, 2021. 
• Smruti Mahapatra, Tarana Parvez Kaovasia, Sufia Maryam Ainechi, Ana Ainechi, Molly Acord, Betty Tyler, Nicholas Theodore and Amir 
Manbachi, ‘Design of an Ultrasound Probe Holder to Minimize Motion Artifact During Sonography’, Design of Medical Devices 
Conference, 2021. 
• Ana Ainechi, Beth Smith, Jennifer Son, Javad Azadi, Smruti Mahapatra, Molly Acord, Tarana Kaovasia, Betty Tyler, Nicholas Theodore 
and Amir Manbachi, ‘How can ultrasound detect microcirculation? A study of frequency requirements to enable visualization of 
microvasculature and tissue perfusion.’, Design of Medical Devices Conference, 2021. 
• Manish Balamurugan, Kathryn Chung, Smruti Mahapatra, Molly Acord, Tarana Parvez Kaovasia, Aliaksei Pustavoitau, and Amir 
Manbachi ‘USDL-OD: A Novel YOLOv4 Model Implementation for Minimizing Cotton Retention during Neurosurgical 
Procedures using Ultrasound Imaging, The International Scoiety for Optics and Photonics (SPIE), 2020. 
COMPUTER SKILLS 
• Windows 10 
• macOS Catalina  
• Microsoft Office 
• MATLAB 
• Python 3.7 
• 3D Slicer 
• ImageJ 
• Minitab 
• Aspen Plus 
• SOLIDWORKS 
LEADERSHIP SKILLS 
Peer Leader                                                                                                                                                                (Dec 2017 – Dec 2018)                                                                                                                  
Center for the Enhancement of Engineering Diversity, Virginia Tech                                                      Blacksburg, VA    
• Organized professional development events for freshmen and mentors 
• Interviewed and hired peer mentors every 
• Evaluated weekly reports from mentors each week during the fall semesters   
Peer Mentor                                                                                                                                                               (Aug 2015 – Nov 2017)                                                                                                                  
Center for the Enhancement of Engineering Diversity, Virginia Tech                                                      Blacksburg, VA    
• Mentored 8-10 freshmen engineering students each fall 
• Women Engineering Support Team (WEST) mentor 
• Coordinated weekly meetings with mentees and provided Peer Leader with weekly reports 
ACTIVITIES 
Alpha Chi Sigma (AXS) – Professional Chemistry Fraternity                          (April 2016 – May 2018)                                                                                                                  
Virginia Tech                                                               Blacksburg, VA    
• Offered free tutoring for general chemistry and organic chemistry 
• Performed weekly science experiments at local elementary school 
• Visited local nursing home regularly 
• Volunteered as a dog walker at animal shelter 
Virginia Tech BIG EVENT                                  (April 2015, April 2016, April 2017)                                                                                                                  
                                                                      Blacksburg, VA    
• Annual day og giving back to the Blacksburg Community 
• Volunteer projects ranging from yard work to house painting 
• Group leader for three consecutive years 
Virginia Tech Relay for Life                                  (April 2016, April 2017, April 2018)                                                                                                                  
                                                                      Blacksburg, VA    
• First ranked and largest collegiate Relay for Life 
• Represented AXS and raise money through face painting and bake sales 
HONORS 
Leslie C. Gates Family Scholarship                      (2014 – 2015) 
Virginia Tech Dean’s List              Fall 2014, Spring 2018, and Fall 2018 
Biographical sketch
Molly Acord is graduating with a Master of Science in Engineering degree in the
field of Biomedical Engineering from The Johns Hopkins University. Here she has
developed her skills as a researcher in the area of focused ultrasound. Her primary
interest is the treatment of glioblastoma.
Molly holds a Bachelor of Science in the field of Chemical Engineering from Virginia
Polytechnic Institute and State University. There she performed research in many
areas including autism spectrum disorder treatment, mimicry of biological surfaces,
and focused ultrasound.
Upon graduation, Molly will transition to industry at a focused ultrasound company
in the Baltimore area.
Outside of research, she spends most of her time with her cat, tending to her plants,
and cooking.
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